Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients
01:07pm, Tuesday, 30'th Jul 2024
IMUNON Inc IMNN stock is surging on Tuesday, with a strong session volume of 117.8 million as per data from Benzinga Pro.
Imunon's stock rockets after ovarian cancer treatment's positive trial results
09:42am, Tuesday, 30'th Jul 2024
Shares of Imunon Inc. skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.
Why Is Imunon (IMNN) Stock Up 259% Today?
08:25am, Tuesday, 30'th Jul 2024
Imunon (NASDAQ: IMNN ) stock is rocketing higher on Tuesday as the clinical-stage company releases data from a Phase 2 clinical trial of IMNN-001. This is the company's treatment candidate for patien
Phase 2 OVATION 2 Study of IMNN-001 a dministered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
04:05pm, Monday, 29'th Jul 2024
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m.
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
08:30am, Monday, 24'th Jun 2024
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NAS
First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial
08:30am, Wednesday, 05'th Jun 2024
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company fo
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-gener
Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript
06:05pm, Monday, 13'th May 2024
Imunon, Inc. (NASDAQ:IMNN ) Q1 2024 Earnings Conference Call May 13, 2024 11:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Michael Tardugno - Executive Chairman Stacy Lindborg -
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
09:00am, Monday, 13'th May 2024
Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
08:00am, Monday, 13'th May 2024
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
08:00am, Wednesday, 08'th May 2024
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08,
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
11:00am, Monday, 06'th May 2024
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacci
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101
08:30am, Thursday, 18'th Apr 2024
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter
IMUNON Reports Compliance with Nasdaq Listing Requirements
08:00am, Thursday, 11'th Apr 2024
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated i
